|
Press Releases |
|
|
|
Saturday, April 29, 2017 |
|
Nanobiotix: 2016 Annual Results |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announces its audited consolidated results for the fiscal year ended December 31, 2016. more info >> |
|
Tuesday, April 4, 2017 |
|
Nanobiotix Expands Its Clinical Development in Head and Neck Cancer and Immuno-Oncology |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced the expansion and acceleration of its clinical development activities. more info >> |
|
Friday, March 24, 2017 |
|
NANOBIOTIX: The Independent Data Monitoring Committee Recommends the Continuation of the Ongoing Phase II/III Trial of NBTXR3 in Soft Tissue Sarcoma |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the local treatment of cancer, today announced that the Independent Data Monitoring Committee (IDMC) has completed the interim evaluation of the Phase II/III trial results (Act.In.Sarc) of NBTXR3 in soft tissue sarcoma. more info >> |
|
Tuesday, March 7, 2017 |
|
Nanobiotix to Present Preclinical Data on Nanoparticle Radioenhancer NBTXR3 at the AACR Annual Meeting 2017 |
NANOBIOTIX today announced the presentation of NBTXR3 preclinical studies demonstrating 1) the antitumor efficacy of NBTXR3 in five different in vivo human cancer models and 2) the antitumor efficacy of NBTXR3 in combination with chemotherapy, in both in vitro and in vivo studies. more info >> |
|
Tuesday, February 7, 2017 |
|
Nanobiotix Appoints Senior Executive from Pharmaceutical Industry, as Chief Operating Officer |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announced today the appointment of Alain Dostie, a senior executive from the pharmaceutical industry, as its Chief Operating Officer (COO). more info >> |
|
Wednesday, February 1, 2017 |
|
NANOBIOTIX: 2016 Review and 2017 Anticipated Milestones |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today provides its activities and achievements during 2016 and an overview of anticipated 2017 milestones. more info >> |
|
Thursday, December 15, 2016 |
|
Nanobiotix Reports Positive Phase I/II Preliminary Data on Feasibility and Safety of NBTXR3 in Liver Cancers Trial |
NANOBIOTIX, a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announces a positive readout of initial data on the safety and feasibility from the first patients treated in its Phase I/II trial evaluating NBTXR3 in liver cancers, including primary (Hepatocellular, HCC) and metastatic tumors. more info >> |
|
Tuesday, November 29, 2016 |
|
Nanobiotix Provides Update on Global Development of Lead Product NBTXR3 |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today provides an update on the global development of its lead product, NBTXR3, across all indications. more info >> |
|
Monday, November 14, 2016 |
|
Nanobiotix Presents NBTXR3 Preclinical Data Demonstrating Its Potential Usage as In Situ Vaccine for Cancer at the Society for Immunotherapy of Cancer Annual Meeting |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announces preclinical data demonstrating that its leading radioenhancer nanoparticle, NBTXR3, actively stimulates the host immune system to attack tumor cells. more info >> |
|
Monday, November 7, 2016 |
|
Nanobiotix' Partner PharmaEngine Has Launched a New NBTXR3 Clinical Trial in Head and Neck Cancers in Asia |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205) today announced that its Asia-Pacific partner, PharmaEngine, has dosed its first patient in a new Phase I/II trial in patients with head and neck cancers patient receiving radiotherapy plus chemotherapy, this October. The trial is evaluating the optimal dose, safety and preliminary efficacy of Nanobiotix's lead product. more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
Dubai FinTech Summit concludes with over 8,000 visitors from 118 countries
May 14, 2024 17:01: JST
|
|
|
Thailand: Ivy launches plum and tamarind juice drinks in SIG XSlimBloc carton packs
May 14, 2024 16:00 HKT/SGT
|
|
|
Dubai FinTech Summit concludes with over 8,000 visitors from 118 countries
May 14, 2024 14:06 HKT/SGT
|
|
|
$9.25 Million in Investments Committed to Start-ups during FinTech World Cup at Dubai FinTech Summit
May 14, 2024 13:02: JST
|
|
|
DENSO and Certhon Introduce Artemy, A Fully Automated Cherry Truss Tomato Harvesting Robot
May 14, 2024 11:02 JST
|
|
|
Rover Provides Permitting Update on Let's Go Lithium Project, NV, USA
May 14, 2024 07:00 HKT/SGT
|
|
|
Global News and Publishing Platform Gnomi Launches Paid Journalism Program
May 13, 2024 23:15 HKT/SGT
|
|
|
$9.25 Million in Investments Committed to Start-ups during FinTech World Cup at Dubai FinTech Summit
May 13, 2024 19:58 HKT/SGT
|
|
|
富士通、スーパーコンピュータ「富岳」の世界ランキング結果を発表
May 13, 2024 19:00: JST
|
|
|
Supercomputer Fugaku retains first place worldwide in HPCG and Graph500 rankings
May 13, 2024 18:32 JST
|
|
|
Eisai's Antiepileptic Drug Fycompa Approved in China for Adjunctive Treatment of Primary Generalized Tonic-Clonic Seizures
May 13, 2024 17:06 JST
|
|
|
Datacloud APAC: Charting the Course for APAC's Cloud Future
May 13, 2024 16:00 HKT/SGT
|
|
|
3rd Annual Clean Power & New Energy 2024
May 13, 2024 14:03 HKT/SGT
|
|
|
Ogier and TOYOTA GAZOO Racing triumph again
May 13, 2024 14:36 JST
|
|
|
日清食品公布2024年首季度业绩
May 13, 2024 13:00 HKT/SGT
|
|
|
|
More News >> |
|
|
|
|
|